Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
14/05/202413:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
14/05/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
14/05/202412:30GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
07/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XLOXilio Therapeutics Inc
01/04/202421:05GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:05GlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:00GlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/03/202411:00Business WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
28/02/202421:01GlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
31/01/202421:01GlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
19/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
08/01/202412:30GlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
03/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202312:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
07/12/202312:30GlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
09/11/202321:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
09/11/202321:10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:08Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
09/11/202321:01GlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
03/11/202320:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
31/10/202313:15GlobeNewswire Inc.Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
27/09/202322:02GlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
07/09/202321:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
07/09/202321:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO